{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T20:22:22Z","timestamp":1788985342140,"version":"build-2803163510"},"reference-count":71,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Psoriasis and psoriatic arthritis (PsA) occasionally coexist with antinuclear antibody (ANA) positivity, cutaneous lupus erythematosus (CLE), or systemic lupus erythematosus (SLE), creating one of the most challenging therapeutic overlap scenarios in immunodermatology. Divergent immune pathways\u2014IL-23\/Th17-driven psoriatic inflammation versus type I interferon-mediated autoimmunity\u2014generate unique vulnerabilities when systemic treatments are used. To synthesize treatment outcomes, lupus-related safety signals, and mechanistic insights across systemic therapies in patients with psoriasis or PsA who also exhibit ANA positivity, CLE, or SLE. A systematic review following PRISMA 2020 guidelines was conducted across PubMed\/MEDLINE, Embase, the Cochrane Library, Scopus, and ClinicalTrials.gov from database inception through 31 October 2025. Thirty-three eligible reports (29 unique clinical studies; 1429 patients) were included and organized into six prespecified overlap subgroups. Mechanistic and translational studies\u2014including ustekinumab and deucravacitinib SLE trial data and reports of IL-17 inhibitor-associated CLE\u2014were reviewed separately to provide contextual interpretation. IL-23 inhibitors were consistently associated with a favorable cross-disease safety profile, with no clear signal for CLE worsening, SLE flares, or drug-induced autoimmunity. IL-17 inhibitors maintained strong psoriatic efficacy but were associated with an increased frequency of de novo or exacerbated CLE. TNF-\u03b1 inhibitors showed the strongest association with ANA seroconversion, anti-dsDNA induction, drug-induced lupus, and lupus flares. Ustekinumab demonstrated a stable safety profile across lupus-spectrum disease despite variable efficacy in formal SLE trials. TYK2 inhibition provided dual modulation of IL-23 and type I interferon pathways and showed emerging utility in psoriasis or PsA coexisting with CLE or SLE. Apremilast, methotrexate, and mycophenolate mofetil remained reliable non-biologic systemic options. Phototherapy was associated with potential risk in ANA-positive or lupus-susceptible populations and therefore requires careful consideration. Interpretation is limited by the predominantly observational nature and heterogeneity of the available evidence. IL-23 inhibition and TYK2 inhibition appear to offer a balanced profile of efficacy and lupus-related safety in psoriatic disease complicated by lupus-spectrum autoimmunity. IL-17 inhibitors and TNF-\u03b1 inhibitors may be associated with higher risk in CLE- or SLE-prone patients and therefore warrant particular caution. Personalized treatment strategies should integrate the relative dominance of psoriatic versus lupus disease, ANA\/ENA profile, CLE subtype, and underlying mechanistic considerations. Prospective, biomarker-driven studies are needed to guide therapy in this increasingly recognized overlap population (PROSPERO registration: CRD420251241279).<\/jats:p>","DOI":"10.3390\/ijms27021093","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:16:59Z","timestamp":1769159819000},"page":"1093","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Systemic Treatment Strategies for Patients with Psoriasis and Psoriatic Arthritis in the Setting of ANA Positivity or Lupus Spectrum Disease: A Comprehensive Systematic Review"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0925-366X","authenticated-orcid":false,"given":"Jeng-Wei","family":"Tjiu","sequence":"first","affiliation":[{"name":"Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 100225, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-1474","authenticated-orcid":false,"given":"Tsen-Fang","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei 100225, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1365-2230.2001.00832.x","article-title":"Psoriasis\u2013epidemiology and clinical spectrum","volume":"26","author":"Christophers","year":"2001","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.rdc.2015.07.001","article-title":"The Epidemiology of Psoriatic Arthritis","volume":"41","author":"Ogdie","year":"2015","journal-title":"Rheum. Dis. Clin. N. Am."},{"key":"ref_6","unstructured":"Wallace, D.J., and Hahn, B.H. (2018). Dubois\u2019 Lupus Erythematosus and Related Syndromes, Elsevier. [9th ed.]."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/art.34473","article-title":"Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus","volume":"64","author":"Petri","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.autrev.2010.08.014","article-title":"SLE diagnosis and treatment: When early is early","volume":"10","author":"Doria","year":"2010","journal-title":"Autoimmun. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41584-019-0272-0","article-title":"Cutaneous lupus erythematosus: New insights into pathogenesis and therapeutic strategies","volume":"15","author":"Wenzel","year":"2019","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.berh.2008.09.008","article-title":"Autoimmune diseases induced by TNF-targeted therapies","volume":"22","author":"Soto","year":"2008","journal-title":"Best. Pract. Res. Clin. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/03009740310000391","article-title":"Disease activity and antinucleosome antibodies in systemic lupus erythematosus","volume":"32","author":"Benucci","year":"2003","journal-title":"Scand. J. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrrheum.2012.106","article-title":"New insights into mechanisms of therapeutic effects of antimalarial agents in SLE","volume":"8","author":"Wallace","year":"2012","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"16039","DOI":"10.1038\/nrdp.2016.39","article-title":"Systemic lupus erythematosus","volume":"2","author":"Kaul","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/BOR.0000000000000522","article-title":"Drug-induced lupus erythematosus: An update on drugs and mechanisms","volume":"30","author":"He","year":"2018","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/ard.2008.092767","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)","volume":"68","author":"Mease","year":"2009","journal-title":"Ann. Rheum. Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/1346-8138.17177","article-title":"Recent findings about antimalarials in cutaneous lupus erythematosus: What dermatologists should know","volume":"51","author":"Teboul","year":"2024","journal-title":"J. Dermatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Zhao, M.H., Cons Molina, F., Aroca, G., Tektonidou, M.G., Mathur, A., Tangadpalli, R., Sun, R., Martin, R., Pellet, P., and Huynh, T.N.P. (2025). Secukinumab in active lupus nephritis: Results from phase III, randomised, placebo-controlled study (SELUNE) and open-label extension study. Rheumatology, keaf536.","DOI":"10.1093\/rheumatology\/keaf536"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1111\/j.1365-2133.2009.09563.x","article-title":"Antinuclear antibodies associate with loss of response to antitumour necrosis factor-alpha therapy in psoriasis: A retrospective, observational study","volume":"162","author":"Pink","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"250","DOI":"10.5114\/pdia.2015.53320","article-title":"Autoimmunogenicity during anti-TNF therapy in patients with psoriasis and psoriatic arthritis","volume":"32","author":"Pirowska","year":"2015","journal-title":"Postep. Dermatol. Alergol."},{"key":"ref_24","first-page":"401","article-title":"Autoantibodies in psoriatic patients treated with anti-TNF-\u03b1 therapy","volume":"12","author":"Bardazzi","year":"2014","journal-title":"J. Dtsch. Dermatol. Ges."},{"key":"ref_25","first-page":"445","article-title":"Induction of Autoantibodies and Autoimmune Diseases in Patients with Psoriasis Receiving Tumor Necrosis Factor Inhibitors","volume":"108","author":"Dauden","year":"2017","journal-title":"Actas Dermosifiliogr."},{"key":"ref_26","first-page":"e72698","article-title":"Secukinumab-Aggravated Disseminated Discoid Lupus Erythematosus Misdiagnosed as Psoriasis","volume":"16","author":"Ye","year":"2024","journal-title":"Cureus"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/09612033221095692","article-title":"Aggravation of discoid lupus erythematosus in a patient with psoriasis and psoriatic arthritis during treatment of secukinumab: A case report and review of literature","volume":"31","author":"Hsieh","year":"2022","journal-title":"Lupus"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"S753","DOI":"10.1097\/RHU.0000000000001511","article-title":"Secukinumab-Induced Lupus Erythematosus: A Case Report and Literature Review","volume":"27","author":"Kaler","year":"2021","journal-title":"J. Clin. Rheumatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e13417","DOI":"10.1111\/dth.13417","article-title":"Secukinumab-induced subacute cutaneous lupus erythematosus","volume":"33","author":"Conforti","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jdcr.2020.02.013","article-title":"Secukinumab-induced chronic discoid lupus erythematosus","volume":"6","author":"Chatzimichail","year":"2020","journal-title":"JAAD Case Rep."},{"key":"ref_31","first-page":"265","article-title":"Secukinumab-induced systemic lupus erythematosus in psoriatic arthritis","volume":"2","author":"Lopes","year":"2023","journal-title":"ARP Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1272\/jnms.JNMS.2023_90-115","article-title":"Change in Antinuclear Antibody Titers during Biologic Treatment for Psoriasis","volume":"90","author":"Miyazaki","year":"2023","journal-title":"J. Nippon Med. Sch."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1001\/archdermatol.2011.185","article-title":"Successful treatment of subacute lupus erythematosus with ustekinumab","volume":"147","author":"Strober","year":"2011","journal-title":"Arch. Dermatol."},{"key":"ref_34","first-page":"e233","article-title":"Two poles of the Th 17-cell-mediated disease spectrum: Analysis of a case series of 21 patients with concomitant lupus erythematosus and psoriasis","volume":"31","year":"2017","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1093\/skinhd\/vzaf058","article-title":"Effective management of psoriasis and psoriatic arthritis in a patient with systemic lupus erythematosus using deucravacitinib, mycophenolate mofetil and hydroxychloroquine","volume":"5","author":"Gewiss","year":"2025","journal-title":"Ski. Health Dis."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/bjd\/ljaf293","article-title":"Tyrosine kinase 2 inhibition improves clinical and molecular hallmarks in subtypes of cutaneous lupus","volume":"193","author":"Wasserer","year":"2025","journal-title":"Br. J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e001517","DOI":"10.1136\/lupus-2025-001517","article-title":"Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: Efficacy on patient-reported outcomes in a phase II randomised trial","volume":"12","author":"Mosca","year":"2025","journal-title":"Lupus Sci. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.jaad.2020.05.074","article-title":"Hydroxychloroquine effects on psoriasis: A systematic review and a cautionary note for COVID-19 treatment","volume":"83","author":"Sachdeva","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s10067-017-3566-0","article-title":"Psoriasis in systemic lupus erythematosus: A single-center experience","volume":"36","author":"Tselios","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1191\/0961203304lu490xx","article-title":"Cutaneous LE or psoriasis: A tricky differential diagnosis","volume":"13","author":"Wohl","year":"2004","journal-title":"Lupus"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.5114\/dr.2025.152182","article-title":"A Systematic Review of Case Reports on the Co-occurrence of Cutaneous Lupus Erythematosus and Psoriasis","volume":"112","author":"Staniszewska","year":"2025","journal-title":"Dermatol. Rev."},{"key":"ref_42","first-page":"180","article-title":"Cutaneous lupus erythematosus, morphea profunda and psoriasis: A case report","volume":"16","year":"2020","journal-title":"Reumatol. Clin. (Engl. Ed.)"},{"key":"ref_43","first-page":"1","article-title":"The coexistence of psoriasis with lupus erythematosus and other photosensitive disorders","volume":"195","author":"Zalla","year":"1996","journal-title":"Acta Derm. Venereol. Suppl."},{"key":"ref_44","first-page":"e84760","article-title":"Systemic Lupus Erythematosus and Psoriasis Overlap: A Case Series","volume":"17","author":"Ali","year":"2025","journal-title":"Cureus"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e001504","DOI":"10.1136\/lupus-2025-001504","article-title":"Comorbid psoriasis in systemic lupus erythematosus: A cohort study from a tertiary referral centre and the National Patient Register in Sweden","volume":"12","author":"Walhelm","year":"2025","journal-title":"Lupus Sci. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/1346-8138.13215","article-title":"Antinuclear antibody formation following administration of anti-tumor necrosis factor agents in Japanese patients with psoriasis","volume":"43","author":"Yanaba","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1111\/1346-8138.14578","article-title":"Increase in antinuclear antibody levels through biologic treatment for psoriasis","volume":"46","author":"Miki","year":"2019","journal-title":"J. Dermatol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"904","DOI":"10.4103\/idoj.IDOJ_164_20","article-title":"The Effect of Biological Agents on Antinuclear Antibody Status in Patients with Psoriasis: A Single-Center Study","volume":"11","author":"Kutlu","year":"2020","journal-title":"Indian Dermatol. Online J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1111\/1346-8138.16102","article-title":"Biologics modulate antinuclear antibodies, immunoglobulin E, and eosinophil counts in psoriasis patients","volume":"48","author":"Sugiura","year":"2021","journal-title":"J. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S0190-9622(84)80267-4","article-title":"The coexistence of systemic lupus erythematosus and psoriasis","volume":"10","author":"Hays","year":"1984","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1590\/S0482-50042010000300003","article-title":"Autoantibodies in patients with psoriatic arthritis on anti-TNF\u03b1 therapy","volume":"50","author":"Viana","year":"2010","journal-title":"Rev. Bras. Reumatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1136\/ard.2004.031286","article-title":"Autoantibodies in biological agent naive patients with psoriatic arthritis","volume":"64","author":"Johnson","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Silvy, F., Bertin, D., Bardin, N., Auger, I., Guzian, M.C., Mattei, J.P., Guis, S., Roudier, J., and Balandraud, N. (2015). Antinuclear Antibodies in Patients with Psoriatic Arthritis Treated or Not with Biologics. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0134218"},{"key":"ref_54","first-page":"27","article-title":"Antinuclear Antibody Status and Effect of Biological Therapy in Psoriatic Arthritis Patients: A Single-Center Study","volume":"29","author":"Kara","year":"2025","journal-title":"Med. J. \u0130zmir Hosp."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"A871","DOI":"10.1136\/annrheumdis-2013-eular.2599","article-title":"AB0277 Antinuclear antibodies in patients with tnf- inhibitors","volume":"72","author":"Eibl","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"ref_56","first-page":"2239","article-title":"Serologically active clinically quiescent systemic lupus erythematosus\u2013predictors of clinical flares","volume":"21","author":"Gladman","year":"1994","journal-title":"J. Rheumatol."},{"key":"ref_57","first-page":"48","article-title":"Coexistence of psoriatic arthritis and systemic lupus erythematosus","volume":"9","author":"Avriel","year":"2007","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15761\/ROM.1000105","article-title":"Association of psoriasis and psoriatic arthritis with systemic lupus erythematosus","volume":"1","author":"Bonilla","year":"2016","journal-title":"Rheumatol. Orthop. Med."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3899\/jrheum.190940","article-title":"Increased Prevalence of Systemic Lupus Erythematosus Comorbidity in Patients with Psoriatic Arthritis: A Population-based Case-control Study","volume":"48","author":"Korkus","year":"2021","journal-title":"J. Rheumatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1080\/24725625.2020.1717741","article-title":"Treatment of psoriatic arthritis complicated by systemic lupus erythematosus with the IL-17 blocker secukinumab and an analysis of the serum cytokine profile","volume":"4","author":"Sato","year":"2020","journal-title":"Mod. Rheumatol. Case Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2174\/0115733971294744240530051404","article-title":"Uncommon Coexistence of Systemic Lupus Erythematosus and Psoriatic Arthritis: A Case-Based Review","volume":"21","author":"Venetsanopoulou","year":"2025","journal-title":"Curr. Rheumatol. Rev."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"151","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1007\/s10067-024-07059-3","article-title":"Prioritizing drug targets in systemic lupus erythematosus from a genetic perspective: A druggable genome-wide Mendelian randomization study","volume":"43","author":"Gao","year":"2024","journal-title":"Clin. Rheumatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1136\/ard-2022-222839","article-title":"Clinical trials in systemic lupus erythematosus: The dilemma-Why have phase III trials failed to confirm the promising results of phase II trials?","volume":"82","author":"Isenberg","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Duan, K., Wang, J., Chen, S., Chen, T., Wang, J., Wang, S., and Chen, X. (2024). Causal associations between both psoriasis and psoriatic arthritis and multiple autoimmune diseases: A bidirectional two-sample Mendelian randomization study. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1422626"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Fija\u0142kowska, A., Wojtania, J., Wo\u017aniacka, A., and Robak, E. (2024). Psoriasis and Lupus Erythematosus-Similarities and Differences between Two Autoimmune Diseases. J. Clin. Med., 13.","DOI":"10.3390\/jcm13154361"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jdermsci.2011.03.002","article-title":"Epidemiology and comorbidities of psoriasis patients in a national database in Taiwan","volume":"63","author":"Tsai","year":"2011","journal-title":"J. Dermatol. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"Mourits","year":"2009","journal-title":"J. Immunol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"85","DOI":"10.3899\/jrheum.2025-0390.PV012","article-title":"Imiquimod-induced onset of disease in lupus-prone nzb\/w f1 mice","volume":"52","author":"Hovd","year":"2025","journal-title":"J. Rheumatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/ng.690","article-title":"Association analyses identify six new psoriasis susceptibility loci in the Chinese population","volume":"42","author":"Sun","year":"2010","journal-title":"Nat. Genet."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/2\/1093\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T09:19:40Z","timestamp":1769159980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/2\/1093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":71,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["ijms27021093"],"URL":"https:\/\/doi.org\/10.3390\/ijms27021093","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]}}}